Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

A Phase 1, Randomized, Single-blinded, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of RN0191 in Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol

Objectives: The primary and secondary objectives of the study are presented below. Exploratory objectives are presented in the body of the protocol.

Primary:

• To determine the safety and tolerability of RN0191 administered as escalating single subcutaneously (SC) doses in adult subjects with elevated low-density lipoprotein-cholesterol

Secondary:

• To evaluate the single-dose pharmacokinetics (PK) of RN0191 in adult subjects with elevated low-density lipoprotein-cholesterol
• To evaluate the pharmacodynamic (PD) effect of RN0191 on serum levels of low-density lipoprotein-cholesterol (LDL-C)
• To evaluate the PD effect of RN0191 on plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Study Overview

• Status: Completed
• Conditions: To Reduce the LDL-C Level in Hypercholesteremia Adult Patients; Combination for Subgroup High LDL-c Patients With Other Comorbidities
• Intervention / Treatment: Drug: RN0191 INJECTION

Detailed Description

This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated low-density lipoprotein-cholesterol. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study. The study only has one part: SAD cohorts with Sentinel Dosing

The starting dose for subjects in Cohort 1 will be 25 mg RN0191 (or placebo). The following are the planned dose levels for subsequent cohorts in the SAD phase:

• Cohort 2: 100 mg RN0191 or placebo
• Cohort 3: 300 mg RN0191 or placebo
• Cohort 4: 500 mg RN0191 or placebo

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Brisbane
    • Herston, Brisbane, Australia, 4006
      • Nucleus Networks

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male and female subjects, aged 18 to 60 years, inclusive.
2. Body mass index between 18 and 32 kg/m2, inclusive, with body weight > 45 kg for females and >50 kg for males.
3. Serum LDL-C ≥100mg/dL (2.6 mmol/L) at screening and Day -1.
4. Fasting triglycerides < 400 mg/dL (<4.52 mmol/L) at screening and Day -1.
5. Adequate complete blood counts (complete blood counts [CBCs]; if outside the reference range, CBC values that are not clinically relevant and are acceptable to the Investigator)
6. Female subjects are eligible to participate if they are confirmed either not women of child-bearing potential (WOCBP), or have a negative urine pregnancy test at Day 1, are not breastfeeding, and willing and able to abide by the contraception guidelines.
7. Male subjects who can produce viable sperm are eligible to participate if they agree to use an adequate method of contraception as per the contraceptive guidance from Screening (signing the ICF) until at least 3 months post dose. Subjects with a partner(s) who is (are) not of childbearing potential are exempt from these requirements.
8. Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. In addition, male subjects must refrain from donating sperm from Screening (signing the ICF) until at least 3 months post dose.
9. Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent

Exclusion Criteria:

1. Male and female subjects, aged 18 to 60 years, inclusive.
2. Body mass index between 18 and 32 kg/m2, inclusive, with body weight > 45 kg for females and >50 kg for males .
3. Serum LDL-C ≥100mg/dL (2.6 mmol/L) at screening and Day -1.
4. Fasting triglycerides < 400 mg/dL (<4.52 mmol/L) at screening and Day -1.
5. Adequate complete blood counts (complete blood counts [CBCs]; if outside the reference range, CBC values that are not clinically relevant and are acceptable to the Investigator).
6. Female subjects are eligible to participate if they are confirmed either not women of child-bearing potential (WOCBP), or have a negative urine pregnancy test at Day 1, are not breastfeeding, and willing and able to abide by the contraception guidelines (signing the ICF).
7. Male subjects who can produce viable sperm are eligible to participate if they agree to use an adequate method of contraception as per the contraceptive guidance in Appendix 3 from Screening (signing the ICF) until at least 3 months post dose. Subjects with a partner(s) who is (are) not of childbearing potential are exempt from these requirements.
8. Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. In addition, male subjects must refrain from donating sperm from Screening (signing the ICF) until at least 3 months post dose.
9. Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Cohort 1 will be 25 mg RN0191 (or placebo)	Drug: RN0191 INJECTION; a sterile solution in each bottle for subcutaneous (SC) injection
Active Comparator: Cohort 1 will be 100 mg RN0191 (or placebo)	Drug: RN0191 INJECTION; a sterile solution in each bottle for subcutaneous (SC) injection
Active Comparator: Cohort 1 will be 300 mg RN0191 (or placebo)	Drug: RN0191 INJECTION; a sterile solution in each bottle for subcutaneous (SC) injection
Active Comparator: Cohort 1 will be 500 mg RN0191 (or placebo)	Drug: RN0191 INJECTION; a sterile solution in each bottle for subcutaneous (SC) injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory objectives are presented in the body of the protocol.	• To determine the safety and tolerability of RN0191 administered as escalating single subcutaneously (SC) doses in adult subjects with elevated low-density lipoprotein-cholesterol	For each subject in the study, the duration of the study clinic visits is approximately 21 weeks from screening to Day 85/EOS examination.

Collaborators and Investigators

• Sponsor: Ikaria Bioscience Pty Ltd
• Investigators: Principal Investigator: Kristi McLendon, MD, Nucleus Network

Study record dates

Study Major Dates

• Study Start (Actual): July 14, 2023
• Primary Completion (Actual): February 24, 2024
• Study Completion (Actual): May 14, 2024

Study Registration Dates

• First Submitted: June 2, 2023
• First Submitted That Met QC Criteria: June 14, 2023
• First Posted (Actual): June 15, 2023

Study Record Updates

• Last Update Posted (Actual): October 10, 2024
• Last Update Submitted That Met QC Criteria: October 8, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Hyperlipidemias; Dyslipidemias; Hypercholesterolemia
• Other Study ID Numbers: RN0191-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No